

Substitute for form 1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



#3  
Application No. 09/960,665  
Applicant: Rosen, et al.  
Filing Date: 9/21/01  
Title: Methods and Compositions for  
Degradation and/or Inhibition  
of HER-Family Tyrosine  
Kinases

Attorney Docket No.: MSK.P-038 -2

RECEIVED  
JAN 30 2002  
TECH CENTER 608/12900

Page 1 of 2

**U.S. PATENT DOCUMENTS**

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
B.K.	4,261,989	Sasaki et al. 424/244	04/14/81
B.K.	5,650,430	Sugimura et al. 514/450	07/22/97
B.K.	5,932,566	Schnur et al. 514/183	08/03/99
B.K.	5,968,921	Gold 514/183	10/19/99
B.K.	6,239,168	Ino et al. 514/450	05/29/01

**FOREIGN PATENT DOCUMENTS**

	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	
B.K.	Munster et al., "Inhibition of Heat Shock Protein 90 Function by Ansamycins Causes the Morphological and Functional Differentiation of Breast Cancer Cells", <i>Cancer Research</i> . 01 April 2001, Volume 61, pp 2945-2952,
B.K.	Schulte et al., "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin", <i>Cancer Chemotherapy and Pharmacology</i> , 1998, Volume 42, pp 273-279
B.K.	Bohen, S.P., "Genetic and Biochemical Analysis of p23 and Ansamycin Antibiotics in the Function of HSP90-Dependent Signaling Proteins", <i>Molecular and Cellular Biology</i> , June 1998, volume 18, no. 6, pp 3330-3339
B.K.	Pratt, W.B., "The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors", <i>Proceedings of the Society for Experimental Biology and Medicine</i> , April 1998, volume 217, no. 4, pp 420-434
B.K.	Scheibel, et al., "Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence", <i>Proceedings of the National Academy of Sciences of the USA</i> , February 17, 1998, volume 95, no. 4, pp 1495-1499

Substitute for form 1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Application No. 09/960,665

Applicant: Rosen, et al.

Filing Date: 9/21/01

Title: Methods and Compositions for  
Degradation and/or Inhibition  
of HER-Family Tyrosine  
Kinases

Attorney Docket No.: MSK.P-038-2

Page 2 of 2

B.K.	Chen, et al., "The Ah Receptor is a Sensitive Target of Geldanamycin-Induced Protein Turnover", <i>Archives of Biochemistry and Biophysics</i> , December 1, 1997, volume 348, no. 1, pp 190-198
B.K.	Landel, et al., "Estrogen Receptor Accessory Proteins Augment Receptor-DNA Interaction and DNA Bending", <i>The Journal of Steroid Biochemistry &amp; Molecular Biology</i> , volume 63, no. 1-3, pp 59-73
B.K.	Bamberger, et al., "Inhibition of Mineralocorticoid and Glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin", <i>Molecular and Cellular Endocrinology</i> , August 8, 1997, volume 131, no. 2, pp 233-240
B.K.	Segnitz, et al., "The Function of Steroid Hormone Receptors s Inhibited by the hsp90-specific Compound Geldanamycin", <i>The Journal of Biological Chemistry</i> , July 25, 1997, volume 272, no. 30, pp 18694-18701

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Bruce K. M.  
Examiner Signature

10/8/02  
Date Considered

Substitute for form 1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

COPY OF PAPERS  
ORIGINALLY FILED

Application No. 09/960,665

Applicant: Rosen, et al.

Filing Date: 9/21/01

Title: Methods and Compositions for  
Degradation and/or Inhibition  
of HER-Family Tyrosine  
Kinases

Attorney Docket No.: MSK.P-038-2

CH CENTER 1600/2900

MAY 14 2002

RECEIVED



Page 1 of 2

**U.S. PATENT DOCUMENTS**

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

**FOREIGN PATENT DOCUMENTS**

	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	
D.K.	Hurst, S. et al., "HSP90 inhibitors block the mitotic checkpoint and are synergistically toxic with spindle poisons", <i>Clinical Cancer Res.</i> , November 1999, Vol. 8, page 3788s, #293
B.K.	Kherfellah, d. et al, "Effect of the combination of topoisomerase I and topoisomerase II inhibitors on rat glioblastoma cells and drug-resistant variants", <i>Pharmacol. Experimental Therapeutics</i> , March 1999, Vol. 40, page 109, #724
B.K.	Stebbins, c. E. et al, "Crystal structure of the Hsp90-Geldanamycin complex: targeting of a protein chaperone by an antitumor agent", <i>Cell</i> , April 1997, Vol. 89, pages 239-240 and 246-248
A.K.	Rosenhagen, M. C. et al, "Synergistic inhibition of the Glucocorticoid receptor by radicicol and benzoquinone ansamycins", <i>Biol. Chem.</i> , March 2001, Vol. 382, pages 499-504

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner Signature

10/10/02  
Date Considered